Company: LGNZZ
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0000886163-25-000063
Chunk: 6

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-11-07
Form: 10-Q
Item: Item 1
Chunk 6
---
)(1,276)Balance at June 30, 2025*19,411 20 358,635 8,494 460,164 827,313 Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes347 — 25,523 — — 25,523 Share repurchase in connection to the 2030 Notes (Note 7)(102)— (15,000)— — (15,000)2030 Convertible Notes hedge and warrant transactions, net of tax (Note 7)— — (21,290)— — (21,290)Share-based compensation— — 14,746 — — 14,746 Unrealized gain on available-for-sale securities, net of tax— — — 78 — 78 Foreign currency translation adjustment, net of tax— — — 750 — 750 Net income (as reported)— — — — 117,273 117,273 ASU 2025-07 adoption: impact on net income for the six months ended June 30, 2025— — — — 778 778 Balance at September 30, 202519,656 $20 $362,614 $9,322 $578,215 $950,171 

*Interim equity balances reflect the impact of ASU 2025-07 adoption in Q3 2025 effective January 1, 2025.

7

Common StockAdditional paid in capitalAccumulated other comprehensive income (loss)Retained earnings Total stockholders’ equitySharesAmountBalance at December 31, 202317,556 $18 $198,696 $(817)$503,016 $700,913 Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes368 — 12,228 — — 12,228 Share-based compensation— — 7,334 — — 7,334 Unrealized loss on available-for-sale securities, net of tax— — — (93)— (93)Net income— — — — 86,139 86,139 Balance at March 31, 202417,924 18 218,258 (910)589,155 806,